However, DVL-1 mRNA levels were significantly highly expressed in PR-negative (p = 0.01), HER2-negative (p = 0.01) and triple-negative status (p = 0.004), further substantiating the idea that DVL-1 expression may serve as a potential diagnostic biomarker for specific subtypes of breast cancer such as triple-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.